Stay updated on INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    Page revision updated: v3.5.0 removed, v3.5.2 added.
    Difference
    0.0%
    Check dated 2026-04-18T13:36:01.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    Added Padova, Italy and removed Padua, Italy from the Locations list.
    Difference
    0.0%
    Check dated 2026-04-04T06:00:37.000Z thumbnail image
  4. Check
    29 days ago
    Change Detected
    Summary
    Napoli, Italy was replaced with Naples, Italy in the location listings, and revision tags were updated to v3.5.0 (added) and v3.4.3 (removed).
    Difference
    0.0%
    Check dated 2026-03-21T00:44:54.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    Revision note updated from v3.4.2 to v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-06T19:49:12.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    Update timestamps were added (2026-02-27, 2026-02-26, 2026-02) and older timestamps (2025-12-12, 2025-11-28, 2025-11) were removed from the page.
    Difference
    0.1%
    Check dated 2026-02-27T19:10:03.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    The site version has been updated from v3.4.1 to v3.4.2; no user-facing changes to the study details page were observed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-13T11:53:11.000Z thumbnail image

Stay in the know with updates to INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.